Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- * The patient, with a history of chronic kidney disease and on various medications, initially arrived at the hospital after experiencing difficulties walking and swelling.
- * Treatment involved intravenous fluids and albumin, resulting in improved kidney function, highlighting the importance of monitoring CK levels in asymptomatic COVID-19 patients, especially those with certain risk factors.
Midostaurin and cyclosporine drug interaction: A case report.
J Clin Pharm Ther
April 2020
St. Luke's Mountain States Tumor Institute, Boise, Idaho.
What Is Known And Objective: Allogeneic stem cell transplantation patients are often on immunosuppression including calcineurin inhibitors post-transplant for prevention of graft-versus-host disease. Recent data suggested that addition of midostaurin, a FLT-3 mutant kinase inhibitor, maintenance can reduce risk of relapse by 46% at 18 months post-transplant.
Case Description: Patient is a post-allogenetic stem cell transplant patient started on midostaurin for maintenance therapy.
P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans.
Mol Pharm
March 2012
Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, United States.
We have shown that the rat can quantitatively predict the verapamil-cyclopsorine A (CsA) drug-drug interaction (DDI) at the human blood-brain barrier (BBB). In addition, the potency (EC(50)) of CsA to inhibit rat BBB P-gp can be predicted from in vitro studies in MDRI-transfected cells. To assess if these excellent agreements extend to other substrates, we determined the magnitude of P-gp-based DDI at the rat BBB between loperamide (Lop) or its metabolite, N-desmethyl Lop (dLop), and escalating CsA blood concentrations.
View Article and Find Full Text PDFSotrastaurin and cyclosporine drug interaction study in healthy subjects.
Biopharm Drug Dispos
July 2010
Novartis Pharmaceuticals, Basel, Switzerland.
Introduction: Sotrastaurin is an immunosuppressant that inhibits protein kinase C and blocks T-lymphocyte activation. The authors determined the effect of combining sotrastaurin with the calcineurin inhibitor cyclosporine on the pharmacokinetics and biomarker responses to both drugs.
Methods: This was a randomized, 4-period, crossover study in 20 healthy subjects who received single oral doses of (1) sotrastaurin 100 mg, (2) cyclosporine 400 mg, (3) 100 mg sotrastaurin with 100 mg cyclosporine and (4) 100 mg sotrastaurin with 400 mg cyclosporine.
Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients.
Int J Cardiol
May 2005
Department of Nephrology, Pitie-Salpetriere Hospital, 83, boulevard de l'hopital, 75013 Paris, France.
Dyslipidemia is frequent in patients with renal failure and in transplant recipient patients. This lead to a wide use of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) in patients with impaired renal function or in patients treated with cyclosporine as post-transplantation immunosuppressive therapy. As a result, it is crucial for those patients' physicians to be aware of how to handle these drugs when renal function is impaired and/or when cyclosporine is co-administered.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!